Bile Duct Cancer Market

Global Bile Duct Cancer Market Size

The global bile duct cancer market was valued at USD 371.34 million in 2025. The global market is anticipated to grow at a CAGR of 14.67% from 2026 to 2034, reaching USD 1,273 million by 2034, up from USD 425.82 million in 2026.

The bile duct is a tube network that connects the liver to the gallbladder. The bile duct transports bile, a liquid produced by the liver and stored in the gallbladder. Cholangiocarcinoma is the medical term for bile duct cancer. Long-term liver inflammation, gallstones, bile duct abnormalities such as cysts, and liver fluke parasite infection, which causes bile duct infection, all contribute to the development of bile duct cancer and exposure to hazardous chemicals and toxins. It is generally a type of cancer that affects the thin tubes that transport bile, the digestive fluid, through the liver. It is a rare but deadly form of cancer, but y yellowing of the skin and eyes are its symptoms.

MARKET DRIVERS

YOY increase in cancer incidence and R&D activities from the pharmaceutical companies to augment the bile duct cancer market growth.

Advancements in all endoscopic imaging techniques with high-tech and minimally invasive stone retrieval products are some of the key growth drivers for the market. In addition, the increasing prevalence of liver infections would increase the demand for biliary tract cancer. Furthermore, the market is growing due to the innovations in the latest launch of technologically advanced devices. Various new cancer treatment programs are being developed to better the cancer situation. Many different types of research are being conducted to find drugs and other cancer necessities that will make patients' lives easier. This improves the advanced healthcare facilities of hospitals and clinics for cancer patients, creating numerous growth opportunities for the biliary tract cancer market. Many hospitals, outpatient surgical centers, and clinics worldwide implement cutting-edge technology and equipment.

The other major factors propelling the growth of the bile duct cancer market are rising expenditure in the healthcare sector, increase in infections such as liver fluke, Awareness of cancer prevention and control, technological innovations, increasing prevalence of chronic diseases, increasing funding from various public and private sectors, high adoption of home care settings, increasing attention to drug development and increasing demand for precision medicine.

Increased exposure to hazardous chemicals used in printing and other applications hurts the livers of industrial workers. As a result, various healthcare industries will likely see increased demand for bile duct cancer treatment. As a result, companies must rationalize Bile Duct Cancer market trends to increase consumption density. Furthermore, the major players are focusing on inorganic strategies such as collaborations to strengthen their product offerings and footprint in the global biliary duct cancer market, contributing to the growth of the bile duct cancer market.

MARKET RESTRAINTS

The restraints to the growth of the global bile duct cancer market are attributed to less Awareness of cholangiocarcinoma and costly cancer treatment in various developing countries. In addition, biliary tract cancer treatments are expensive due to the high-cost processes of cancer diagnosis, treatment, and clinical trials. Therefore, the lack of clinical data, a low diagnosis rate, and regulatory agencies in various countries frowning on expensive drugs will further limit the global market growth.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Treatment Type Insights

Based on the treatment type, the chemotherapy segment held a significant share of the bile duct cancer market in 2024 and is anticipated to register a healthy CAGR during the forecast period owing to ongoing innovative research into improving chemotherapy, availability of a wide range of chemotherapeutic agents, and studying new drugs and drug combinations using clinical trials.The surgery segment is also anticipated to grow at a promising CAGR during the forecast period as it is used in many areas like Whipple procedure, partial hepatectomy, liver transplantation, palliative surgery, biliary diversion, biliary stent placement, surgical removal of the bile ducts, and in treatment of bile duct cancers.

By Product Insights

Based on the product, the 5-fluorouracil (5-FU) segment dominated the market in 2023. This is because 5-fluorouracil has improved patient survival in various cancers. For instance, patients with resected BTC may benefit significantly from a 5-FU regimen, regardless of whether they have gallbladder carcinoma (GBC) or cholangiocarcinoma (CCA). Furthermore, high-risk patients, such as those with vascular invasion or node-positive disease, are more likely to benefit.The cisplatin and gemcitabine segments are also anticipated to progress at a healthy CAGR since their administration helps treat advanced biliary tract cancers. Treatment with nab-paclitaxel plus gemcitabine-cisplatin prolongs the overall survival compared to historical treatment with gemcitabine-cisplatin alone.

By End-User Insights

Based on the end-user, the hospitals and clinics segment led the market in 2023.On the other hand, the academic institute's segment would also show promising growth owing to increasing demand for more Awareness of health-related education, including cancer, throughout the global

REGIONAL ANALYSIS

Geographically, the North American region accounted for a significant share of the market in 2024 owing to many ongoing research activities, the prevalence of bile duct cancer, a growing number of research activities, a rapid and easy production approval process, the growing number of outreach programs, and the increase in government-private companies.

Additionally, most people who are often affected by cancer in the United States are between 70 and 75. As a result, the prevalence of bile duct and liver cancer has risen alarmingly in North America. Because of the prevalence of bile duct cancer, the United States is committed to increasing the demand for angiography equipment. In the United States, approximately 6,000 people are diagnosed with bile duct cancer each year. Furthermore, ongoing oncology research, improved government reimbursement policies, and advanced healthcare facilities are some factors driving market growth in this region.

Asia-Pacific is also expected to grow over the forecast period owing to the quick and easy production approval process, increasing incidence of biliary tract cancer patients, an increasing number of outreach programs, and increasing public and private investments in this region. Moreover, liver fluke infection of the bile ducts is becoming common in developing countries, which is the cause for the increase in the number of bile duct cancer patients.

Due to a large population base, a large pool of potential patients with bile duct cancer, and a growing awareness of the importance of initiating new treatment therapies, the Food and Drug Administration (FDA) recently approved pemigatinib for use in the United States. The medication is an oral kinase inhibitor that may be useful in patients with cholangiocarcinoma.

In addition, Europe has a sizable market share for bile duct cancer. The Middle East and Africa are growing slowly due to the weak African economy, but the region is expected to grow in the coming years.

KEY MARKET PLAYERS

Companies playing a vital role in the global bile duct cancer market profiled in this report are

• Johnson & Johnson
• Bayer AG
• Celgene Corp
• Bristol-Myers Squibb
• Pfizer, Inc.
• F. Hoffmann-La Roche Ltd.
• Sanofi
• Novartis AG
• Merck & Co., Inc.
• ConMed Corporation
• Boston Scientific Corporation

GLOBAL BILE DUCT CANCER MARKET NEWS

• In September 2022, based on the TOPAZ-1 clinical trial results, the Food and Drug Administration approved durvalumab in combination with Gemcitabine and cisplatin for people with biliary tract cancer.
• In October 2022, Lytgobi, a cancer drug developed by Taiho Oncology, became the third FDA-approved treatment for bile duct cancer caused by FGFR2 genetic changes. The accelerated approval for Taiho's drug follows regulatory approvals for Incyte and QED Therapeutics products that target the same genetic signature.

MARKET SEGMENTATION

This research report has segmented and sub-segmented the global bile duct cancer market based on product, treatment type, end-user & region.

By Treatment Type

• Surgery
• Chemotherapy
• Radiation Therapy

By Product

• 5-fluorouracil
• Gemcitabine
• Cisplatin
• Capecitabine
• Oxaliplatin

By End-User

• Hospital and Clinics
• Academic Institutes

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa